Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fidgetin-like 2 siRNA
- Development stage
- Preclinical
- Lead developer
- MicroCures
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
Fidgetin-like 2 siRNA is a small interfering RNA (siRNA) therapeutic candidate developed by MicroCures to promote tissue repair and nerve regeneration. The drug works by silencing the expression of Fidgetin-like 2 (FL2), a microtubule-severing enzyme that normally restricts cell migration and axonal growth by destabilizing the microtubule cytoskeleton. By knocking down FL2, the siRNA allows for increased microtubule polymerization and stability, thereby accelerating the migration of cells (such as keratinocytes and fibroblasts) into wound sites and promoting the elongation of axons following nerve injury. MicroCures is investigating this approach for various indications, including neurotrophic keratitis, corneal alkaline burns, and peripheral nerve injuries.
- Other names
- Fidgetin-like 2-targeting siRNAFidgetin-like2-targeting siRNAFidgetin-like-2-targeting siRNA
02
Targets
FL2 (Fidgetin-like protein 2)
Beyond the preview
Go deeper on fidgetin-like 2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fidgetin-like 2 siRNA.